Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Andrew Morris, Peter Lea, Patrick Schnable, Andy Ferrin

Premium

Andrew Morris has joined SQI Diagnostics' board of directors.

Morris has been president and CEO of the Toronto-based molecular test developer since June. He replaces SQI founder Peter Lea, who has resigned from the board. SQI said that Lea will continue to serve the company as an adviser.


Patrick Schnable has been named Iowa Corn Promotion Board Endowed Chair in Genetics, a new faculty position within Iowa State University's agronomy department. In connection with the appointment, the board has invested $2 million to support the position and its research.

Schnable is an agronomy professor and is director of ISU's Center for Plant Genomics.


Andy Ferrin has left Golden Helix to become a sales executive at Oracle Health Sciences. Ferrin had served as executive vice president of sales, business development, and services at Golden Helix, a Bozeman, Mont.-based bioinformatics company for the past six years.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.